|
|
|
|
|
4,6-dikloro-2-propylthiopyrimidine-5-amine; 4,6-dikloro-2-(propylthio) -5-PyriMidinaMine; 4,6-Dichloro-2-(propylthio)pyrimidin-5-amine; Tecagrelor InterMediate 3; 5-Pirimidinamin, 4,6-dikloro-2-(propylthio)-;
4,6-dikloro-2-(propylsulfanyl) -5-pirimidinamin; 4,6-Dichloro-5-amino-2-propylthiopyrimidine |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Itilizasyon |
Famasetik Entèmedyè: Se yon entèmedyè kle pou Ticagrelor (non mak Brilinta®/Brilique®) anti-{0}} plakèt. Ticagrelor se yon inibitè reseptè P2Y12 yo itilize pou anpeche boul nan san nan pasyan ki gen sendwòm kardyovaskulèr egi (ACS) oswa enfaktis myokad (MI), epi yo itilize konpoze sa a nan pwosesis sentèz engredyan aktif pharmaceutique Ticagrelor (API).
Sentèz òganik ak R & D famasetik: Li sèvi kòm yon blòk bilding itil nan rechèch ak devlopman nan dwòg anti - tronbotik ak konpoze heterocyclic ki gen rapò. Li se travay tou nan sentèz echèl laboratwa - ak optimize pwosesis pou devlopman nouvo dwòg nan domèn maladi kadyovaskilè.
|
Baj popilè: cas:145783-15-9 4,6-dichloro-2-propylthiopyrimidine-5-amine, Lachin, manifaktirè, founisè, faktori, koutim, wholesale
![CAS 376608-65-0 2-((3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy)etanòl L-tatarik asid](/uploads/24095/small/cas-376608-65-03cd94.png)